title: Clinical Applications of Molecular Imaging in the Management of Prostate Cancer.
abstract: At the heart of selecting an optimal management strategy for men with prostate cancer is accurately determining a given patient's clinical stage and extent of disease. Molecular imaging with PET using properly selected radiotracers offers the opportunity for improved contrast resolution over conventional imaging and thus increased sensativity for detecting sites of disease. In addition, molecular imaging provides the prospect of obtaining functional or biological information regarding a patient's cancer. To date, several PET radiotracers have been developed for prostate cancer imaging. This review summarizes the potential clinical applications of molecular imaging in the management of men with prostate cancer.
authors.affiliation: Department of Urology, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Marburg 118, Baltimore, MD 21287, USA. Electronic address: mgorin1@jhmi.edu.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Gorin
authors.affiliation: The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
authors.forename: Steven P
authors.initials: SP
authors.lastname: Rowe
authors.affiliation: The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
authors.forename: Samuel R
authors.initials: SR
authors.lastname: Denmeade
mesh_terms: D006801:Humans; D008297:Male; D057054:Molecular Imaging / Q000379:methods*; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy; D064129:Prostatic Neoplasms, Castration-Resistant / Q000000981:diagnostic imaging; D019275:Radiopharmaceuticals
chemical_list: D019275:Radiopharmaceuticals
keywords: Cancer staging; Molecular imaging; PET; Prostate cancer